Tejas Savant
Stock Analyst at Morgan Stanley
(2.15)
# 1,531
Out of 4,667 analysts
222
Total ratings
39.42%
Success rate
-5.57%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCYT Veracyte | Maintains: Underweight | $26 → $28 | $39.20 | -28.57% | 13 | Nov 18, 2024 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $32 → $21 | $15.30 | +37.25% | 2 | Nov 18, 2024 | |
| NTRA Natera | Maintains: Overweight | $132 → $176 | $167.88 | +4.84% | 12 | Nov 14, 2024 | |
| ILMN Illumina | Reinstates: Equal-Weight | $156 | $131.68 | +18.47% | 5 | Nov 12, 2024 | |
| IQV IQVIA Holdings | Maintains: Overweight | $280 → $265 | $194.38 | +36.33% | 10 | Nov 4, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $655 → $680 | $512.84 | +32.59% | 12 | Sep 20, 2024 | |
| TXG 10x Genomics | Maintains: Overweight | $50 → $46 | $13.32 | +245.35% | 11 | Aug 13, 2024 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Equal-Weight | $11 → $10 | $4.82 | +107.47% | 12 | Aug 13, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Equal-Weight | $4 → $2 | $1.72 | +16.28% | 13 | Aug 12, 2024 | |
| AKYA Akoya Biosciences | Downgrades: Equal-Weight | $4 → $3 | $2.16 | +38.89% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $29 | $20.14 | +43.99% | 15 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $44 | $58.15 | -24.33% | 1 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $6.36 | +528.93% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $86 → $82 | $78.04 | +5.07% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $6.13 | +14.19% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $15.36 | +10.68% | 12 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $10 | $4.42 | +126.24% | 11 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $52 → $55 | $59.00 | -6.78% | 11 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $16 | $6.57 | +143.53% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.34 | +156.41% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.17 | +215.46% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $1.08 | +154.63% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $3.46 | +44.51% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.29 | +336.68% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $30.68 | +137.94% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $187.90 | +33.05% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.19 | +320.17% | 5 | May 12, 2022 |
Veracyte
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $39.20
Upside: -28.57%
Myriad Genetics
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $15.30
Upside: +37.25%
Natera
Nov 14, 2024
Maintains: Overweight
Price Target: $132 → $176
Current: $167.88
Upside: +4.84%
Illumina
Nov 12, 2024
Reinstates: Equal-Weight
Price Target: $156
Current: $131.68
Upside: +18.47%
IQVIA Holdings
Nov 4, 2024
Maintains: Overweight
Price Target: $280 → $265
Current: $194.38
Upside: +36.33%
Thermo Fisher
Sep 20, 2024
Maintains: Overweight
Price Target: $655 → $680
Current: $512.84
Upside: +32.59%
10x Genomics
Aug 13, 2024
Maintains: Overweight
Price Target: $50 → $46
Current: $13.32
Upside: +245.35%
Maravai LifeSciences Holdings
Aug 13, 2024
Downgrades: Equal-Weight
Price Target: $11 → $10
Current: $4.82
Upside: +107.47%
Pacific Biosciences of California
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.72
Upside: +16.28%
Akoya Biosciences
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $2.16
Upside: +38.89%
Jul 29, 2024
Maintains: Overweight
Price Target: $28 → $29
Current: $20.14
Upside: +43.99%
Jul 9, 2024
Initiates: Overweight
Price Target: $44
Current: $58.15
Upside: -24.33%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $6.36
Upside: +528.93%
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $86 → $82
Current: $78.04
Upside: +5.07%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $6.13
Upside: +14.19%
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $15.36
Upside: +10.68%
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $4.42
Upside: +126.24%
Aug 30, 2023
Maintains: Overweight
Price Target: $52 → $55
Current: $59.00
Upside: -6.78%
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $6.57
Upside: +143.53%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.34
Upside: +156.41%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.17
Upside: +215.46%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $1.08
Upside: +154.63%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $3.46
Upside: +44.51%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.29
Upside: +336.68%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $30.68
Upside: +137.94%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $187.90
Upside: +33.05%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.19
Upside: +320.17%